Immunocore Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
Immunocore Holdings PLC reports results for the quarter ended June 30 - Earnings Summary
Immunocore Holdings PLC IMCR.OQ reported a quarterly adjusted loss of 2 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -20 cents. The mean expectation of thirteen analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -25 cents to 32 cents per share.
Revenue rose 18.3% to $115.93 million from a year ago; analysts expected $110.37 million.
Immunocore Holdings PLC's reported EPS for the quarter was a loss of 2 cents.
The company reported a quarterly loss of $808 thousand.
Immunocore Holdings PLC shares had risen by 4.9% this quarter and lost 4.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 160.2% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Immunocore Holdings PLC is $73.00, about 54.4% above its last closing price of $33.29
This summary was machine generated from LSEG data August 6 at 01:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | 0.01 | -0.02 | Missed |
Mar. 31 2026 | -0.26 | 0.25 | Beat |
Dec. 31 2025 | -0.24 | -0.60 | Missed |
Sep. 30 2025 | -0.26 | 0.00 | Beat |